

# Waiving the Medicaid Best Price Rule Could Boost Savings from a Commercial Value-Based Arrangement by \$4 Billion: Citations

## Citations

- <sup>1</sup> Kaiser Family Foundation, “Poll: Nearly 1 in 4 Americans Taking Prescription Drugs Say It’s Difficult to Afford Their Medicines, including Larger Shares Among Those with Health Issues, with Low Incomes and Nearing Medicare Age,” March 2019. <https://www.kff.org/health-costs/press-release/poll-nearly-1-in-4-americans-taking-prescription-drugs-say-its-difficult-to-afford-medicines-including-larger-shares-with-low-incomes>
- <sup>2</sup> Nathan E. Wineinger, Yunyue Zhang, and Eric J. Topol, “Trends in Prices of Popular Brand-Name Prescription Drugs in the United States,” JAMA, May 2019. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2734804>
- <sup>3</sup> Marylou Buyse, Stephen Carter, and Kyle Sarnataro, “Factors Influencing the Implementation of Value-Based Contracting Between Pharmaceutical Manufacturers and Payers,” Journal of Clinical Pathways, May 2018. <https://www.journalofclinicalpathways.com/article/factors-influencing-implementation-value-based-contracting-between-pharmaceutical>
- <sup>4</sup> American Association of Retired Persons, “Rx Price Watch Report: Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans: 2017 Year-End Update,” June 2019. <https://www.aarp.org/content/dam/aarp/ppi/2019/06/trends-in-retail-prices-of-specialty-prescription-drugs-year-end-update.doi.10.26419-2Fppi.00073.001.pdf>

The brief is available at: [www.uhg.com/medicaid-best-price-research](http://www.uhg.com/medicaid-best-price-research).